| Info Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Out- side |
| | | | |
|
| | | | |
Result : Searchterm 'T1 Weighted' found in 3 terms [] and 53 definitions []
| previous 46 - 50 (of 56) nextResult Pages : [1] [2 3 4 5 6 7 8 9 10 11 12] | | | | Searchterm 'T1 Weighted' was also found in the following services: | | | | |
| | |
| |
|
| | | | | Further Reading: | News & More:
|
|
| |
| | | | | |
| |
|
Resovist® is an organ-specific MRI contrast agent, used for the detection and characterization of especially small focal liver lesions.
Resovist® consists of superparamagnetic iron oxide ( SPIO) nanoparticles coated with carboxydextran, which are accumulated by phagocytosis in cells of the reticuloendothelial system (RES) of the liver. The uptake of Resovist® Injection in the reticuloendothelial cells results in a decrease of the signal intensity of normal liver parenchyma on both T2- and T1 weighted images.
Most malignant liver tumors do not contain RES cells and therefore do not uptake the iron particles. The resulting imaging effect is an improved contrast between the tumor (bright) and the surrounding tissue (dark).
Resovist® can be injected as an intravenous bolus, which allows immediate imaging of the liver and reduces the overall examination time. A dynamic imaging strategy after bolus injection supports to characterize lesions.
In comprehensive clinical trials, it demonstrated an excellent safety profile.
In 2001, Resovist® was approved for the European market.
See also Superparamagnetic Iron Oxide.
Resovist® competed with Primovist™, the other liver imaging agent of Bayer Schering Pharma AG. Due to this reason, the production of Resovist® has been abandoned in 2009.
Drug Information and Specification T2/T1, Predominantly negative enhancement PHARMACOKINETIC RES-directed CONCENTRATION 0.5 mol Fe/L DOSAGE Less than 60 kg = 0.9 ml, greater than 60 kg = 1.4 ml PREPARATION Finished product PRESENTATION
Pre-filled syringes of 0.9 and 1.4 mL DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information TERRITORY TRADE NAME DEVELOPMENT STAGE DISTRIBUTOR Japan Resovist® approved - Australia Resovist® Approved - | | | | • View the DATABASE results for 'Resovist®' (6).
| | | | Further Reading: | News & More:
|
|
| |
| | | | | |
| |
|
| | | | • View the DATABASE results for 'SHU 555 C' (2).
| | | | |
| | | Searchterm 'T1 Weighted' was also found in the following services: | | | | |
| | | | | | | |
| |
|
Signal intensity interpretation in MR imaging has a major problem.
Often there is no intuitive approach to signal behavior as signal intensity is a very complicated function of the contrast-determining tissue parameter, proton density, T1 and T2, and the machine parameters TR and TE. For this reason, the terms T1 weighted image, T2 weighted image and proton density weighted image were introduced into clinical MR imaging.
Air and bone produce low-intensity, weaker signals with darker images. Fat and marrow produce high-intensity signals with brighter images.
The signal intensity measured is related to the square of the xy-magnetization, which in a SE pulse sequence is given by
Mxy = Mxy0(1-exp(-TR/T1)) exp(-TE/T2) (1)
where Mxy0 = Mz0 is proportional to the proton or spin density, and corresponds to the z-magnetization present at zero time of the experiment when it is tilted into the xy-plane. See also T2 Weighted Image and Ernst Angle. | | | | • View the DATABASE results for 'Signal Intensity' (56).
| | | • View the NEWS results for 'Signal Intensity' (1).
| | | | Further Reading: | | Basics:
|
|
News & More:
| |
| |
| | | | |
| | | |
|
| |
| Look Ups |
| |